COMMUNIQUÉS West-GlobeNewswire

Curia Unveils Brand Refresh at CPHI WW in Milan

07/10/2024 - 15:49

The refined brand highlights Curia’s key capabilities and personalized approach across small molecules, generic APIs and biologics ALBANY, N.Y., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, [...]

New York Medical Device Development Legacy Company MIDI Expands to Toronto

07/10/2024 - 15:35

MIDI is expanding to Toronto to join Canada’s largest MedTech ecosystem, celebrating over 50 years of medical device development excellence TORONTO , Oct. 07, 2024 (GLOBE NEWSWIRE) -- MIDI , a leader in medical device [...]

Sanara MedTech Inc. Announces Changes to Its Board of Directors

07/10/2024 - 15:15

FORT WORTH, TX, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . -- Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a medical technology company focused on improving [...]

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

07/10/2024 - 15:05

MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

07/10/2024 - 15:05

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that [...]

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

07/10/2024 - 15:00

BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells Two trial-in-progress oral presentations to feature Phase II study design of oral covalent menin inhibitor [...]

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07/10/2024 - 15:00

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations [...]

VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland

07/10/2024 - 15:00

— QSIVA now available in all Scandinavian countries — AMSTERDAM, Oct. 07, 2024 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, today announced the availability of QSIVA ® (phentermine and topiramate modified- [...]

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results

07/10/2024 - 15:00

Achieved 35% increase in total revenue compared to prior year period LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens [...]

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

07/10/2024 - 14:55

– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks [...]

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

07/10/2024 - 14:45

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic [...]

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

07/10/2024 - 14:45

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz ® -PDT using the BF-RhodoLED or the RhodoLED XL lamp Supplemental New Drug Application (sNDA) supported by two Phase 1 [...]

Body & Brain Wellness: Bringing the Benefits of Yoga and Tai Chi to Corporate and Retreat Settings

07/10/2024 - 11:21

Body & Brain Wellness offers holistic wellness programs for corporate settings and retreats. The sessions provide participants with practical tools for managing stress and improving well-being MESA, Ariz., Oct. 07, [...]

Sai Life Sciences releases Sustainability Report 2024

07/10/2024 - 11:03

HYDERABAD, India, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO) [1] , published its Sustainability Report for 2023- [...]

Myricx Bio Announces Appointment of Paolo Paoletti MD as an Independent Non Executive Director

07/10/2024 - 10:46

Team Expansion and Move to New London Facilities LONDON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads [...]

Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia’s healthcare transformation strategy

07/10/2024 - 10:00

October 7, 2024 Jakarta, Indonesia and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Siloam Hospitals Group, Indonesia’s leading private healthcare provider [...]

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

07/10/2024 - 09:00

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to [...]

Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in asthma patients

07/10/2024 - 08:08

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under an exclusive clinical [...]

IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies

07/10/2024 - 08:00

PRESS RELEASE IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies Consortium includes leading research institutions, NHS Trusts and industry members and [...]